Prosecution Insights
Last updated: November 20, 2026

John David Moore, USPTO Patent Examiner

Listed by the USPTO as MOORE, JOHN DAVID

Tech Center 1700 • Art Units: 1638 1644 1687 1799

This examiner grants 61% of resolved cases

Analysis

MOORE, JOHN DAVID examines in Tech Center 1700 and Art Unit 1638. The record contains 54 resolved cases, with a 61.1% allowance rate and a 28.3% interview lift. The median time to allowance is 1277 days. The listed companies are Translate Bio Inc., Sana Biotechnology Inc., and Fujifilm Holdings Corporation. The listed firms are NOVICK, KIM & LEE, PLLC, dba NKL Law, SUGHRUE MION, PLLC, and BIRCH STEWART KOLASCH & BIRCH, LLP.

The allowance rate is more than twice the interview lift, so the overall outcome measure and the interview measure tell different parts of the prosecution story. The 54 resolved cases provide a larger base than a single-digit record, while the 1277-day median signals that successful prosecution may require time. Counsel can use the listed entities to identify subject-matter and drafting patterns in related files. The figures support targeted review of claim amendments, interviews, and final resolution paths rather than reliance on the allowance rate alone.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

61.1%
Allow Rate
-3.9% vs TC avg
119
Total Applications
+28.3%
Interview Lift
1277
Avg Prosecution Days
Based on 54 resolved cases, 2023–2026

Rejection Statute Breakdown

5.9%
§101 Eligibility
16.5%
§102 Novelty
38.4%
§103 Obviousness
34.2%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
19028665 PRODUCTION METHOD OF MESENCHYMAL STEM CELL Non-Final OA FUJIFILM Corporation
18472847 GENETICALLY MODIFIED MICE EXPRESSING COMPONENTS OF HUMAN CELLULAR IMMUNE SYSTEM Non-Final OA Regeneron Pharmaceuticals, Inc.
18537479 REAGENTS AND METHODS FOR PRODUCING ARTERIAL HEMOGENIC ENDOTHELIUM, HEMATOPOIETIC PROGENITORS, AND LYMPHOID CELLS THEREBY Non-Final OA Wisconsin Alumni Research Foundation
17930810 ADAPTATION OF PLATFORM HOSTS TO IGF- MEDIA Non-Final OA Amgen Inc.
18858543 METHOD FOR CONVERTING HUMAN SOMATIC CELLS INTO PROLIFERATIVE NEURAL STEM CELLS Non-Final OA KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION
18880108 ESTABLISHMENT OF IMMORTALIZED ERYTHROID PROGENITOR CELL LINE WITH SUPERIOR CAPABILITY OF DIFFERENTIATING INTO RED BLOOD CELLS BY USING GENETIC OVEREXPRESSION COMBINATION, PREPARATION METHOD THEREFOR, AND USE THEREOF Non-Final OA IUCF-HYU (Industry-University Cooperation Foundation Hanyang University)
18241669 METHODS OF DETERMINING PROTEIN REDUCTION SUSCEPTABILITY Final Rejection Sanofi
18290436 CARTILAGE MODEL AS A SUBSTITUTE FOR ANIMAL MODELS AND METHODS FOR EVALUATING EFFECTIVENESS OR TOXICITY OF DRUGS USING THE SAME Non-Final OA KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
18376459 METHOD FOR PREPARING COMPOSITION COMPRISING MESENCHYMAL STEM CELL, EXTRACELLULAR VESICLE PRODUCED BY MESENCHYMAL STEM CELL, AND GROWTH FACTOR, COMPOSITION PREPARED BY THE METHOD, AND USE OF COMPOSITION FOR TREATING ARTHRITIS Non-Final OA GWO XI STEM CELL APPLIED TECHNOLOGY CO., LTD.
18800672 NOVEL RAPID DRUG DISCOVERY FOR SEPSIS AND AGENTS FOR USE AS SEPSIS THERAPY Non-Final OA THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY
18692497 Screening Method Using Brown Adipocytes Final Rejection Kyoto Prefectural Public University Corporation
18720534 MODIFIED PARAMYXOVIRIDAE FUSION GLYCOPROTEINS Non-Final OA Sana Biotechnology, Inc.
18682798 GENETICALLY MODIFIED CELLS FOR ALLOGENEIC CELL THERAPY Non-Final OA Sana Biotechnology, Inc.
18289361 MANUFACTURING METHOD OF MEMORY T CELLS Non-Final OA Yasuhito Tokumoto
17906448 ANTIGEN-SPECIFIC T CELL RECEPTORS AND T CELL EPITOPES Non-Final OA BioNTech Cell & Gene Therapies GmbH

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Who Appears Before This Examiner

Top companies before this examiner

Law firms appearing most often

Frequently Asked Questions

What is examiner John David Moore's allowance rate?

61.1% of resolved applications examined by John David Moore were allowed (54 resolved cases), compared with 49.3% across Art Unit 1638 over the last five years.

Does an interview help with examiner John David Moore?

This examiner's interview lift is +28.3 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.

How long does examiner John David Moore take to allow a patent?

Applications allowed by John David Moore took 1,277 days on average from filing to allowance.

Which art unit does examiner John David Moore work in?

John David Moore examines applications in Art Unit 1638 in Tech Center 1700 (Chemistry & Materials).

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month